Detection of EGFR gene mutations in tumor tissues

The presence of an EGFR gene mutation is a predictor of response to EGFR inhibitor therapy in patients with locally advanced and metastatic non-small cell lung cancer. The presence of the L858R mutation and deletion in exon 19 of the EGFR gene serves as a predictor of the efficacy of the use of the EGFR inhibitor osimertinib in the adjuvant setting in patients with resectable stage IB-IIIA non-small cell lung cancer.

Within 11 days. The specified time does not include the day of biomaterial collection